Benztropine
From Wikipedia, the free encyclopedia
 |
|
|
Benztropine
|
|
| Systematic (IUPAC) name | |
| 3-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane | |
| Identifiers | |
| CAS number | |
| ATC code | N04 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C21H25NO |
| Mol. mass | 307.429 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | 3-6 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | oral, IM, IV |
Benztropine (Cogentin®) is an anticholinergic drug principally used for the treatment of:
- Drug-induced parkinsonism, akathisia and acute dystonia;
- Parkinson disease; and
- Idiopathic or secondary dystonia.
[edit] Indications
It is used in patients with schizophrenia to reduce the side effects of antipsychotic treatment, such as parkinsonism and akathisia.
Benztropine is also a second-line drug for the treatment of Parkinson's disease. It improves tremor but not rigidity or bradykinesia.
Benztropine is also sometimes used for the treatment of dystonia, a rare disorder that causes abnormal muscle contraction, resulting in twisting postures of limbs, trunk, or face.
[edit] Side effects
These are principally anticholinergic:
- Dry mouth
- Blurred vision
- Cognitive changes
- Constipation
- Urinary retention
- Tachycardia
- Anorexia
- Psychosis (usually in overdose)
Some studies suggest that use of anticholinergics increases the risk of tardive dyskinesia, a long-term side effect of antipsychotics.[1][2] Other studies have found no association between anticholinergic exposure and risk of developing tardive dyskinesia.[3]
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
